Text and Data Mining valid from 2019-02-06
Received: 4 December 2018
Accepted: 28 January 2019
First Online: 6 February 2019
Ethics approval and consent to participate
: The use of <sup>177</sup>Lu-DOTATATE in Neuroendocrine tumours was approved by the Institute Ethics Committee, AIIMS. Ref. No IESC/T-279/2009-10. Consent was given by all the patients to undergo <sup>177</sup>Lu-DOTATATE therapy.
: We have taken the consent for publication from the patients.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.